Particle.news

UK Launches First Large-Scale Phase 3 Maternal Trial For Group B Strep Vaccine

The study seeks to boost maternal antibodies passed to babies through the placenta to prevent life‑threatening newborn infections.

Overview

  • This week the BEATRIX trial began active recruitment at 10 UK sites, including the Princess Royal Hospital in Shropshire and the John Radcliffe Hospital in Oxford.
  • Eligible pregnant women between 24 and 36 weeks’ gestation are randomised to a single injection of an investigational GBS vaccine or a saline placebo and will be followed with their babies for about 14 and 12 months respectively.
  • A Shropshire mother, Menna Hulme, was reported as the first person in Europe to enrol and local research teams are using her story to encourage more pregnant people to sign up.
  • Group B streptococcus causes sepsis, pneumonia and meningitis in newborns and is estimated to kill about 50 UK babies a year and leave around 70 survivors with long‑term disabilities.
  • Investigators say that if the vaccine proves protective and achieves high coverage, modelling cited by the study suggests it could prevent tens of thousands of deaths and many preterm births globally and reduce newborn antibiotic exposure.